Haemonetics Corp Director Charles J. Dockendorff Not Seeking Re-Election

What Happened

• Haemonetics Corporation (HAE) filed a Form 8-K (Item 5.02) reporting that on April 27, 2026 Charles J. Dockendorff informed the company he will not stand for re-election at the 2026 Annual Meeting of Shareholders.
• Mr. Dockendorff has served on Haemonetics’ Board since 2014 and currently serves on the Audit Committee and the Governance and Compliance Committee. He will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. The filing notes his decision is not the result of any disagreement with the company. The 8-K was signed May 1, 2026.

Key Details

• Date of notice: April 27, 2026.
• Board tenure: Director since 2014.
• Committee roles: Member of the Audit Committee and the Governance and Compliance Committee.
• Continued service: Will remain a director and committee member until the 2026 Annual Meeting; no dispute with the company cited.

Why It Matters

• A board member departure can affect board composition and committee expertise—investors should note the anticipated vacancy on the board and on key oversight committees (Audit; Governance & Compliance).
• Because Mr. Dockendorff will remain in place until the annual meeting and the company disclosed no disagreement, this is a planned departure rather than an abrupt governance conflict.
• Investors should watch upcoming proxy and annual meeting materials for the company’s nominee to replace him and any related changes to committee assignments.